Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02953821 · ClinicalTrials.gov registry record · Phase 4
Acthar Gel for Active Systemic Lupus Erythematosus (SLE)
A Phase 4 study of Lupus Erythematosus, Systemic, sponsored by Mallinckrodt.
- Completed
- Registry status
- Phase 4
- Development phase
- 172
- Enrollment target
- 20
- Study locations
NCT02953821 is a Phase 4 study of Lupus Erythematosus, Systemic that has completed, run by Mallinckrodt. The registered enrollment target is 172 participants, below the 197-participant average among 29 other Lupus Erythematosus, Systemic trials with a reported enrollment target (13% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT02953821, a Phase 4 study of Lupus Erythematosus, Systemic, has completed, sponsored by Mallinckrodt.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 172 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial is to study Acthar Gel in participants with active systemic lupus erythematosus (SLE). The doctor will assign eligible patients to one of two groups (like flipping a coin). Participants will receive the treatment assigned to their group for 24 weeks: * Acthar Gel * Placebo Gel, which looks like Acthar Gel, but has no medicine in it. The doctor or his staff will take measurements and ask questions to: * see how well the gel is working * see how safe it is for patients with SLE
Conditions Studied
Interventions
- DRUG Placebo Gel
- DRUG Acthar Gel
Study Locations (20)
Florida
- Center for Rheumatology Immunology and Arthritis - Fort Lauderdale
- San Marcus Research Clinic - Miami
- Advanced Pharma CR - Miami
- Millennium Research - Ormond Beach
Other
- Aprillus Asistencia e Investigación - Buenos Aires
- Consultorios Médicos Dr. Catalán Pellet - Buenos Aires
- Centro Medico Privado de Reumatología - San Miguel de Tucumán
- Biomedica Research Group - Santiago
California
- C.V. Mehta MD Medical Corporation - Hemet
- Inland Rheumatology Clinical Trials - Upland
Tennessee
- West Tennessee Physicians' Alliance - Jackson
- Office of Ramesh C. Gupta, MD - Memphis
Texas
- Accurate Clinical Research - Houston
- Sun Research Institute - San Antonio
Nevada
- Office of George Timothy Kelly MD - Las Vegas
New York
- NewYork-Presbyterian Columbia University Medical Center - New York
North Carolina
- DJL Clinical Research - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2016-12-16 |
| Est. Completion | 2019-10-25 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02953821
The ClinicalTrials.gov registry entry for NCT02953821 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 197-participant average among 29 other Lupus Erythematosus, Systemic trials with a reported enrollment target (13% lower). The listed sponsor is Mallinckrodt, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lupus Erythematosus, Systemic appearing as the primary indexed condition, and to 2 interventions - of which Placebo Gel is the first listed.
NCT02953821 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, Other, California.
Frequently Asked Questions
What is clinical trial NCT02953821 about?
NCT02953821 is a clinical study titled "Acthar Gel for Active Systemic Lupus Erythematosus (SLE)". This trial is to study Acthar Gel in participants with active systemic lupus erythematosus (SLE). The doctor will assign eligible patients to one of two groups (like flipping a coin). Participants will receive the treatment assigned to their group for 24 weeks: * Acthar Gel * Placebo Gel, which l...
What is the current status of trial NCT02953821?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 172 participants. The study started on 2016-12-16. Estimated completion is 2019-10-25.
What conditions does trial NCT02953821 study?
This clinical trial studies the following conditions: Lupus Erythematosus, Systemic.
What interventions are being tested in trial NCT02953821?
The interventions under investigation include: Placebo Gel (DRUG), Acthar Gel (DRUG).
Who is sponsoring clinical trial NCT02953821?
This trial is sponsored by Mallinckrodt, which has 69 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02953821 being conducted?
This trial has 20 study locations across California, Florida, Nevada, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lupus Erythematosus, Systemic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Belimumab in Early Lupus
RECRUITING · Phase 4
-
Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE)
RECRUITING
-
A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
RECRUITING · Phase 3
-
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
RECRUITING · Phase 1
-
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RECRUITING · Phase 1
-
Dose Response of Exercise for Arthritis Management
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.